Normal Komplikasyonsuz Gebeliklerde ve Mekonyumlu Gebeliklerde PAPP-A Sonuçlarının ve Doğum Parametrelerinin Karşılaştırılması

Abstract

Amaç: Bu çalışmada, birinci ve ikinci trimester tarama testi parametreleri, normal komplikasyonsuz gebelikler ile mekonyumla komplike olmuş gebeliklerde karşılaştırılarak bu parametrelerin doğum parametreleri üzerindeki etkilerini değerlendirmek amaçlanmıştır. Bu analiz, maternal serum gebelikle ilişkili plazma proteini A ve alfa-fetoprotein düzeylerinin mekonyumla boyanmış amniyotik sıvı için faydalı belirteçler olma potansiyelini ortaya koyarak klinik stratejilerin ve izlem yaklaşımlarının geliştirilmesine katkı sağlayabilecektir. Gereç ve Yöntemler: Bu çalışma retrospektif olgu-kontrol çalışmasıdır. Çalışma kapsamında 1238 gebe taranmış, ikili ve üçlü tarama testi sonuçları birlikte bulunan 528 gebe çalışmaya dahil edilmiştir. Bulgular: Mekonyumla boyanmış amniyotik sıvıya sahip gebelerde, bu durumu olmayanlara kıyasla biyobelirteç düzeyleri anlamlı olarak farklıydı; gebelikle ilişkili plazma proteini A MoM düzeyleri sırasıyla 0,9±0,1 ve 1,2±0,2 idi (p=0,012), alfa-fetoprotein MoM düzeyleri ise sırasıyla 1,3±0,5 ve 0,9±0,0 idi (p=0,009). Mekonyumla boyanmış amniyotik sıvıya sahip olan ve olmayan gebeler arasında fetal distres oranları anlamlı farklılık göstermekteydi; sırasıyla 11 vaka (%10) ve 10 vaka (%2,4) (p=0,001). Yenidoğan yoğun bakım ihtiyacı ise mekonyumla boyanmış amniyotik sıvı görülen gebeliklerde istatistiksel olarak anlamlı şekilde daha yüksekti (n=30 (27.3%) vs. n=61(14.6%), p=0,02). Sonuç: Çalışmamız, azalmış maternal serum gebelikle ilişkili plazma proteini A MoM düzeylerinin ve artmış maternal serum alfa-fetoprotein MoM düzeylerinin mekonyumla boyanmış amniyotik sıvı ile ilişkili olduğunu göstermektedir.

Keywords

• Mekonyumla boyanmış amniyotik sıvı
• PAPP-A
• AFP
• fetal distres
• maternal serum tarama testleri

THE COMPARISON OF PAPP-A RESULTS AND BIRTH PARAMETERS IN NORMAL PREGNANCIES WITHOUT COMPLICATIONS AND IN PREGNANCIES WITH MECONIUM

Abstract

Objective: In the present study, we compare first and second trimester screening test parameters in uncomplicated pregnancies with those in pregnancies complicated by meconium to assess their impact on birth outcomes. This analysis may uncover the potential of maternal serum pregnancy-associated plasma protein-A and alpha-fetoprotein levels as useful markers for meconium-stained amniotic fluid, thereby enhancing clinical strategies and monitoring approaches. Material and Methods: The current study had a retrospective case-control design. In the study, a total of 1238 pregnant women were screened, and 528 who had both double and triple screening results were included. Results: Pregnant women with meconium-stained amniotic fluid exhibited significantly different biomarker levels compared to those without. Specifically, the pregnancy-associated plasma protein A MoM levels were 0.9±0.1 versus 1.2±0.2 (p=0.012), and the alpha-fetoprotein MoM levels were 1.3±0.5 versus 0.9±0.0 (p=0.009), respectively. Fetal distress rates differed significantly between pregnant women with and without meconium-stained amniotic fluid, with 11 cases (10%) compared to 10 cases (2.4%) respectively (p=0.001). The requirement for neonatal intensive care was statistically significantly higher in pregnancies with meconium-stained amniotic fluid (n=30 (27.3%) vs. n=61 (14.6%), p=0.02). Conclusion: Our study demonstrates that decreased maternal serum pregnancy-associated plasma-protein-A MoM levels, coupled with increased maternal serum alpha fetoprotein MoM levels are associated with meconium-stained amniotic fluid.

Keywords

• Meconium-stained amniotic fluid
• PAPP-A
• AFP
• fetal distress
• maternal serum screening tests

References

1. Boldt HB, Conover CA. Pregnancy-associated plasma protein-A (PAPP-A): A local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm IGF Res. 2007;17(1):10-18.
2. Bale LK, Conover CA. Disruption of insulin-like growth factor-II imprinting during embryonic development rescues the dwarf phenotype of mice null for pregnancy-associated plasma protein-A. J Endocrinol. 2005;186(2):325-331.
3. Lawrence JB, Oxvig C, Overgaard MT et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A. 1999;96(6):3149-3153.
4. Gómez Arriaga PI, Herraiz I, LópezJiménez EA, Escribano D, Denk B, Galindo A. Uterine artery Doppler and sFlt-1/PlGF ratio: Prognostic value in early-onset pre-eclampsia. Ultrasound Obstet Gynecol. 2014;43(5):525-532.
5. Kulaksizoglu S, Kulaksizoglu M, Kebapcilar AG, Torun AN, Ozcimen E, Turkoglu S. Can first-trimester screening program detect women at high risk for gestational diabetes mellitus? Gynecol Endocrinol. 2013;29(2):137-140.
6. Yazdani S, Rouholahnejad R, Asnafi N, Sharbatdaran M, Zakershob M, Bouzari Z. Correlation of pregnancy outcome with quadruple screening test at second trimester. Med J Islam Repub Iran. 2015;29:281.
7. Huerta Enochian G, Katz V, Erfurth S. The association of abnormal alpha-fetoprotein and adverse pregnancy outcome: Does increased fetal surveillance affect pregnancy outcome? Am J Obstet Gynecol. 2001;184(7):1549-1553.
8. Olesen AW, Westergaard JG, Olsen J. Perinatal and maternal complications related to postterm delivery: A national register-based study, 1978-1993. Am J Obstet Gynecol. 2003;189(1):222-227.

9. Navakauskiene R, Baronaite S, Matuzevicius D et al. Identification and characterization of amniotic fluid proteins incident to normal, preeclampsia and polyhydramnios pregnancies. Current Proteomics. 2016;13(3):206-217.
10. Turrado Sánchez EM, De Miguel Sánchez V, Macía Cortiñas M. Correlation between PAPP-A levels determined during the first trimester and birth weight at full-term. Reprod Sci. 2023;30(11):3235-3242.
11. Livrinova V, Petrov I, Samardziski I et al. Clinical Importance of low level of PAPP-A in first trimester of pregnancy - An obstetrical dilemma in chromosomally normal fetus. Open Access Maced J Med Sci. 2019;7(9):1475-1479.
12. Zizzo AR, Kirkegaard I, Henriksen TB, Ulbjerg N. Pregnancy‐associated plasma protein A levels and neonatal complications in post‐date pregnancies. Prenat Diagn. 2013;33(10):965-972.
13. Nathan L, Leveno KJ, Carmody TJ, Kelly MA, Sherman ML. Meconium: A 1990s perspective on an old obstetric hazard. Obstet Gynecol. 1994;83(3):329-332.
14. Menzhulina E, Vitrou J, Merrer J et al. Integration of clinical features in a computerized cardiotocography system to predict severe newborn acidemia. Eur J Obstet Gynecol Reprod Biol. 2025;307:78-83.
15. Fernández VR, Cajal CNLR, Ortiz EM, Naveira EC. Intrapartum and perinatal results associated with different degrees of staining of meconium stained amniotic fluid. Eur J Obstet Gynecol Reprod Biol. 2018;228:65-70.
16. Gallo DM, Romero R, Bosco M et al. Meconium-stained amniotic fluid. Am J Obstet Gynecol. 2023;228(5s):S1158-s1178.
17. Khalil A, Syngelaki A, Maiz N, Zinevich Y, Nicolaides KH. Maternal age and adverse pregnancy outcome: A cohort study. Ultrasound Obstet Gynecol. 2013;42(6):634-643.
18. Lin L, Sun B, Wang X, Zhang R, Lin J, Yan J. The mediating effects of gestational diabetes mellitus and hypertensive disorders of pregnancy between maternal advanced age, previous caesarean section and the risk of small or large for gestational age newborns: A multicentric prospective cohort study in southern China. J Glob Health. 2025;15:04053.
19. Gao J, Xiao Z, Chen C et al. Development and validation of a small for gestational age screening model at 21-24 weeks based on the real-world clinical data. J Clin Med. 2023;12(8):2993
20. Swiercz G, Zmelonek Znamirowska A, Szwabowicz K et al. Navigating uncertain waters: First-trimester screening's role in ıdentifying neonatal complications. J Clin Med. 2024;13(7):1982.
21. Chen Y, Dai X, Hu T, Jiang C, Pan Y. Clinical value of prenatal screening markers in early pregnancy combined with perinatal characteristics to predict fetal growth restriction. Transl Pediatr. 2024;13(7):1071.
22. Santolaya Forgas J, Burd LI, Burton BK. Clinical significance of low levels of second-trimester maternal serum human chorionic gonadotropin. Fetal Diagn Ther. 1994;9(6):362-366.
23. Hershkovitz R, de Swiet M, Kingdom J. Mid-trimester placentation assessment in high-risk pregnancies using maternal serum screening and uterine artery Doppler. Hypertens Pregnancy. 2005;24(3):273-280.
24. Vayssière C, Haumonte JB, Chantry A et al. Prolonged and post-term pregnancies: guidelines for clinical practice from the French College of Gynecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2013;169(1):10-16.
25. Zheng J, Wang T, Sun H et al. Genetic correlation between fetal nuchal translucency thickening and cystic hygroma and exploration of pregnancy outcome. Sci Rep. 2024;14(1):27191.